coronavirus
caus
spectrum
ill
asymptomat
diseas
respiratori
failur
earli
report
coronaviru
infect
suggest
infect
mild
sar
epidem
associ
signific
morbid
mortal
septemb
novel
coronaviru
identifi
old
man
saudi
arabia
second
case
identifi
qatari
patient
hospit
unit
kingdom
two
coronavirus
genet
ident
similar
isol
obtain
bat
juli
coronaviru
studi
group
name
new
viru
middl
east
respiratori
syndrom
coronaviru
decemb
case
worldwid
death
epidemiolog
clinic
manifest
diseas
describ
spectrum
ill
asymptomat
infect
sever
respiratori
failur
death
overal
mortal
rate
remain
importantli
known
effect
treatment
increas
merscov
case
report
jeddah
region
saudi
arabia
describ
chang
epidemiolog
outcom
report
clinic
featur
treatment
outcom
patient
admit
region
referr
hospit
jeddah
saudi
arabia
king
fahd
gener
hospit
hospit
jeddah
kingdom
saudi
arabia
region
coronaviru
referr
center
icu
bed
one
infecti
diseas
physician
serv
hospit
januari
decemb
patient
admit
transfer
king
fahd
hospit
posit
mer
coronaviru
pcr
clinic
nasal
swab
nasopharyng
aspir
includ
pcr
test
perform
ministri
health
region
lab
jeddah
magna
pure
compactmagna
pure
roch
autom
system
use
extract
rna
sampl
primer
probe
upe
orf
target
merscov
use
tib
molbiol
germani
along
master
mix
roch
light
cycler
ii
roch
use
amplifi
upe
orf
gene
target
sampl
test
posit
upe
orf
gene
target
cycl
threshold
time
less
consid
confirm
case
posit
neg
control
use
monitor
amplif
process
check
inhibit
amplif
medic
chart
patient
review
data
abstract
standard
data
collect
form
infecti
diseas
train
physician
demograph
clinic
laboratori
data
enter
databas
understand
epidemiolog
age
categor
hypotens
defin
blood
pressur
mm
hg
tachypnea
respiratori
rate
greater
hypoxia
oxygen
satur
thrombocytopenia
platelet
millimet
leukopenia
defin
white
blood
cell
count
cellscub
millimet
leukocytosi
white
blood
cell
count
cellscub
millimet
renal
insuffici
defin
creatinin
mgdl
liver
function
abnorm
defin
lactat
dehydrogenas
ldh
ulit
alanin
transaminas
alt
ulit
aspart
aminotransferas
ast
ulit
immunosuppress
defin
aid
histori
organ
transplant
neutropenia
known
malign
take
immunosuppress
medic
congenit
immunodefici
pregnanc
consid
immunosuppress
state
modifi
acut
physiolog
chronic
health
evalu
apach
score
calcul
use
age
temperatur
mean
arteri
blood
pressur
respiratori
rate
potassium
creatinin
acut
renal
failur
comorbid
condit
estim
sever
ill
estim
use
puls
oximetri
oxygen
satur
result
hematocrit
calcul
multipli
hemoglobin
time
three
statist
analys
perform
use
stata
softwar
version
colleg
station
tx
percent
distribut
clinic
variabl
among
patient
surviv
die
compar
use
fisher
exact
test
multivari
logist
regress
done
treatment
administ
sever
ill
determin
treatment
associ
surviv
mycophenol
mofetil
includ
logist
regress
analysi
patient
receiv
mycophenol
mofetil
surviv
associ
sever
ill
treatment
administ
assess
perform
linear
regress
treatment
administ
onto
modifi
apach
score
total
case
thirti
patient
saudi
nation
foreign
nation
median
age
year
old
iqr
male
n
twentyon
patient
exposur
known
patient
mer
coronaviru
healthcar
worker
none
patient
anim
exposur
two
patient
pilgrimag
mecca
overal
patient
least
one
comorbid
condit
seventeen
patient
diabet
hypertens
end
stage
renal
diseas
eight
coronari
arteri
diseas
six
patient
immunosuppress
two
pregnant
fortynin
patient
document
fever
cough
report
short
breath
thirteen
patient
diarrhea
vomit
complain
sore
throat
clinic
find
present
includ
eight
patient
hypotens
tachypnea
patient
hypoxia
previous
report
laboratori
find
nonspecif
fourteen
patient
anem
thrombocytopen
leukopen
mani
patient
liver
function
abnorm
twentythre
elev
alt
elev
ast
thirtytwo
patient
elev
ldh
patient
elev
ck
patient
elev
creatinin
patient
receiv
varieti
novel
treatment
includ
immunosuppress
antivir
fortytwo
patient
receiv
broadspectrum
antibiot
five
receiv
hydrocortison
thirti
one
patient
receiv
antivir
treatment
twentythre
patient
treat
interferon
beta
eight
treat
interferon
alpha
varieti
antivir
combin
use
eight
patient
receiv
mycophenol
mofetil
seven
patient
receiv
combin
interferon
beta
nineteen
patient
requir
intens
care
unit
icu
care
patient
receiv
extracorpor
membran
oxygen
ecmo
patient
treat
icu
patient
receiv
ecmo
die
recent
cohort
compar
survivor
nonsurvivor
surviv
associ
male
gender
vomit
admiss
elev
respiratori
rate
abnorm
lung
exam
physic
exam
work
healthcar
worker
histori
hypertens
elev
alt
clearanc
mer
cov
repeat
pcr
test
receiv
mycophenol
mofetil
beta
interferon
tabl
contrast
marker
sever
diseas
like
hypotens
hypoxemia
chest
radiograph
abnorm
leukocytosi
elev
creatinin
thrombocytopenia
anemia
renal
failur
associ
death
treatment
given
base
indic
base
clinic
assess
infecti
diseas
consult
team
thirtyon
patient
receiv
antivir
ribavirin
alpha
beta
interferon
patient
receiv
immunosuppress
medic
patient
receiv
combin
alpha
interferon
ribavirin
beta
interferon
ribavirin
beta
interferon
alon
two
patient
receiv
alpha
interferon
alon
eight
patient
receiv
mycophenol
mofetil
seven
receiv
combin
betainterferon
five
patient
receiv
hydrocortison
two
combin
beta
interferon
ribavirin
combin
alpha
interferon
ribavirin
eight
patient
given
mycophenol
mofetil
surviv
therefor
mycophenol
mofetil
could
evalu
model
result
univari
analysi
demonstr
improv
surviv
patient
treat
betainterferon
mycophenol
mofetil
multivari
analysi
includ
marker
sever
ill
demonstr
strong
associ
sever
ill
reduc
surviv
associ
treatment
beta
interferon
surviv
mycophenol
mofetil
evalu
model
tabl
analyz
relationship
sever
ill
treatment
administ
beta
interferon
mycophenol
mofetil
given
less
sever
ill
patient
tabl
merscov
emerg
diseas
initi
epidemiolog
describ
indepth
clinic
studi
role
therapi
incomplet
understood
clinic
featur
merscov
describ
sever
larg
case
seri
pauciti
literatur
therapi
result
rel
larg
number
patient
demonstr
similar
clinic
featur
mortal
previou
studi
cohort
treatment
beta
interferon
mycophenol
mofetil
may
predict
surviv
greatest
predictor
surviv
sever
ill
present
improv
diagnost
demonstr
expand
spectrum
diseas
includ
less
sever
case
previous
report
understand
merscov
caus
acut
respiratori
diseas
syndrom
one
third
patient
present
gastrointestin
symptom
fever
seen
patient
cough
gastrointestin
symptom
seventysix
percent
patient
comorbid
ill
commonli
chronic
renal
failur
diabet
heart
diseas
may
partial
relat
epidemiolog
increas
diseas
transmiss
healthcar
set
rather
true
host
risk
factor
laboratori
find
nonspecif
consist
viral
infect
thrombocytopenia
lymphopenia
commonli
describ
patient
forti
three
percent
acut
kidney
injuri
cxr
abnorm
bibasilar
infiltr
common
find
outcom
sever
ill
patient
remain
poor
requir
icu
care
icu
set
requir
invas
ventil
median
day
addit
mechan
ventil
sever
patient
receiv
extracorp
membran
oxygen
ecmo
support
ventil
nonrandom
data
world
health
organ
five
six
patient
receiv
ecmo
die
fiftyeight
requir
renal
replac
therapi
hospit
patient
die
sever
ill
partial
explain
widespread
lung
diseas
caus
merscov
appear
mortal
patient
requir
intens
care
extrem
high
although
autopsi
data
avail
explant
lung
infect
merscov
caus
widespread
infect
alveolar
diseas
clinic
featur
cohort
similarli
also
show
high
proport
patient
fever
cough
short
breath
almost
one
third
patient
gastrointestin
symptom
cohort
consist
ill
patient
hypotens
tachypnea
hypoxia
thirti
seven
percent
requir
icu
care
patient
receiv
ecmo
similar
previou
result
patient
receiv
ecmo
die
known
effect
treatment
mer
cov
mani
compound
screen
vitro
possibl
activ
coronaviru
howev
vivo
efficaci
subject
clinic
investig
vitro
data
suggest
merscov
inhibit
host
interferon
product
variou
molecular
pathway
mycophen
acid
activ
agent
prodrug
mycophenol
mofetil
cyclosporin
strongli
inhibit
mer
coronaviru
human
monkey
cell
line
even
inhibit
sar
coronaviru
interferon
alpha
interferon
beta
reduc
mer
coronaviru
replic
explant
lung
tissu
vivo
compar
host
respons
two
patient
mer
coronaviru
differ
outcom
patient
abl
clear
mer
cov
infect
abl
mount
interferon
respons
patient
die
low
level
interferon
alpha
suggest
therapeut
role
interferon
combin
interferon
alpha
ribavirin
use
success
rhesu
monkey
infect
mer
coronaviru
small
case
seri
betainterferon
seem
even
potent
inhibitor
mer
coronaviru
vitro
one
small
studi
except
high
mortal
rate
use
interferon
beta
treatment
found
differ
mortal
interferon
beta
use
interferon
alpha
use
data
albeit
retrospect
cohort
support
find
interferon
beta
associ
decreas
mortal
limit
data
efficaci
treatment
regiment
virul
diseas
present
data
retrospect
cohort
ill
patient
merscov
result
evalu
clinic
efficaci
beta
interferon
beta
alpha
interferon
ribavirin
mycophenol
mofetil
addit
routin
support
care
forti
five
percent
patent
patient
receiv
interferon
beta
cohort
sixteen
percent
patient
receiv
interferon
alpha
patient
patient
patient
receiv
ribavirin
either
conjunct
interferon
alpha
interferon
beta
patient
receiv
mycophenol
mofetil
patient
receiv
beta
interferon
mofetil
improv
surviv
howev
confound
sever
ill
present
beta
interferon
patient
receiv
mycophenol
mofetil
surviv
howev
small
number
could
analyz
independ
efficaci
mycophenol
mofetil
rel
larg
seri
merscov
case
primari
limit
studi
retrospect
review
case
random
trial
thu
subject
confound
seen
cohort
use
modifi
apach
score
without
clinic
variabl
may
underestim
associ
sever
ill
reduc
surviv
importantli
mortal
patient
receiv
addit
therapi
modul
immun
respons
low
eight
patient
receiv
mycophenol
mofetil
studi
surviv
henc
may
reason
studi
agent
control
trial
studi
review
approv
john
hopkin
univers
institut
review
board
director
health
affair
data
support
find
manuscript
addit
data
avail
upon
request
